Chrocee 200 Capsule

About Chrocee 200 Capsule

Chrocee 200 is a 200 mg capsule containing ribavirin, an antiviral medicine used in combination for chronic hepatitis C. It is not used alone, and a doctor decides the dose and course.

There are 5 brands of Ribavirin listed in Bangladesh. The lowest listed price is Celbarin 200 mg Capsule at ৳ 35.00 per unit.

What is Chrocee 200 Capsule?

Chrocee 200 is a capsule form of ribavirin, 200 mg, made by Advanced Chemical Industries PLC. It belongs to a group of medicines used for hepatic viral infections, specifically chronic hepatitis C. It is prescribed together with other antiviral drugs and is not used as a single treatment. It is for patients with compensated liver disease, including some adults with HIV coinfection. Ribavirin may interfere with viral nucleic acid synthesis, though the exact way it works is not fully clear. Only a qualified doctor can decide if this medicine is suitable and how long it should be taken.

Uses of Chrocee 200

Chrocee 200 is used to treat chronic hepatitis C virus infection in adults, always in combination with other antiviral medicines. It is for patients with compensated liver disease who have not previously been treated with interferon alpha, and for adult patients with both hepatitis C and HIV. It should never be used alone. Your doctor will confirm whether this medicine is appropriate for your situation and will decide the full treatment plan.

How to use Chrocee 200

Chrocee 200 is a capsule taken by mouth. The dose, how often you take it, and how long you continue are decided by your doctor based on your condition and other medicines you receive. Do not change the dose or stop treatment on your own. Your doctor will assess your response during treatment and may adjust or stop the medicine. Ask your doctor or pharmacist for clear instructions about taking the capsule.

Side effects of Chrocee 200

Common side effects with combination therapy include psychiatric and central nervous system effects, severe eye disorders, and dental or periodontal problems. In children and adolescents, growth inhibition may occur and can be irreversible in some cases. Contact your doctor promptly if you notice mood changes, eye problems, or any unusual symptoms. Your doctor will monitor you and decide if any side effect needs attention or a change in treatment.

Safety and precautions

Chrocee 200 must not be used during pregnancy because it can harm the fetus. Women who may become pregnant should not take it. Before starting, patients need a negative pregnancy test, must use at least two forms of contraception, and have monthly pregnancy tests. Male patients must avoid fathering a child during treatment and for several months after. Do not breastfeed while taking this medicine. Tell your doctor if you have blood disorders such as thalassemia major or sickle-cell anemia, or if you take didanosine or azathioprine. Your doctor will decide if it is safe for you.

Frequently asked questions

How should Chrocee 200 be taken?

Chrocee 200 is a capsule taken by mouth. Your doctor decides the exact dose, how often to take it, and the length of treatment. Do not change or stop the medicine without medical advice. Ask your doctor or pharmacist if you are unsure about how to take it.

What is Chrocee 200 used for and what kind of medicine is it?

Chrocee 200 contains ribavirin, an antiviral medicine. It is used in combination with other antiviral drugs to treat chronic hepatitis C infection in adults with compensated liver disease, including some patients with HIV. It is never used alone. Your doctor will decide if it is right for you.

What side effects should I watch for with Chrocee 200?

Watch for psychiatric or central nervous system effects, severe eye problems, and dental or periodontal issues. Children may have growth inhibition. Tell your doctor promptly if you notice any unusual symptoms. Your doctor will monitor you and decide if treatment needs to change.

Who should not take Chrocee 200?

Chrocee 200 must not be used during pregnancy. It is also not for people with hemoglobinopathies such as thalassemia major or sickle-cell anemia, or for those taking didanosine. Tell your doctor about all your medicines and health conditions before starting treatment, so they can decide if it is safe for you.

Indications

Ribavirin is indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with other antiviral drugs in patients with compensated liver disease not previously treated with interferon alpha and in adult CHC patients coinfected with HIV. Ribavirin should not be used alone.

Pharmacology

Ribavirin is a synthetic nucleoside which has inhibitory action against respiratory syncytial virus, influenza virus and herpes simplex virus. The mechanism of action is not clear. It may act at several sites including cellular enzymes to interfere with viral nucleic acid synthesis. The mono- and triphosphate derivatives are known to be responsible for the antiviral action of the compound.

Dosage & Administration

The recommended duration of treatment for patients previously untreated with interferon is 24 to 48 weeks. After 24 weeks of treatment virologic response should be assessed. Treatment discontinuation should be considered in any patient who has not achieved an HCV RNA below the limit of detection of the assay by 24 weeks. There are no safety and efficacy data on treatment for longer than 48 weeks in the previously untreated patient population. In patients who relapse following interferon therapy, the recommended duration of treatment is 24 weeks. There are no safety and efficacy data on treatment for longer than 24 weeks in the relapse patient populations.

Ribavirin + Interferon: Genotype Ribavirin Daily Interferon alpha-2a Duration or interferon alpha-2b.
  • All <75 kg: (400+600) mg 3 MIU 3 times weekly 48 weeks Genotypes subcutaneously (Genotype1&4)
  • >75 kg: (600+600) mg 24 weeks (Genotype2&3)
Ribavirin + Peg-Interferon: Genotype Ribavirin Daily Peg-Interferon alpha-2a Duration or Peg-interferon alpha-2b:
  • 1 & 4 < 75 kg: (400+600) mg 180 gm once weekly 48 weeks
  • > 75 kg: (600+600) mg subcutaneously 2 & 3 (400+400) mg 24 weeks
Ribavirin may be administered without regard to food, but should be administered in a consistent manner. Drink plenty of water while being treated with this medication; drinking water will decrease the risk of serious side effects.

Interaction

Nucleoside reverse transcriptase inhibitors or reduce dose or discontinue interferon, ribavirin or both with worsening toxicities

Azathioprine: Concomitant use of azathioprine with ribavirin has been reported to induce severe pancytopenia and may increase the risk of azathioprine-related myelotoxicity.

Contraindications

Women who are pregnant. Ribavirin may cause fetal harm when administered to a pregnant woman. Ribavirin is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Patients with hemoglobinopathies (e.g., thalassemia major or sickle-cell anemia). In combination with didanosine. Reports of fatal hepatic failure, as well as peripheral neuropathy, pancreatitis and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials.

Side Effects

The most common adverse reactions in adults receiving combination therapy are psychiatric and central nervous system effects, severe ocular disorder, dental and periodontal disorders & growth inhibition in children and adolescents that may be irreversible in some patients. The most common adverse reactions in pediatric subjects were similar to those seen in adults.

Pregnancy & Lactation

Pregnancy Category X. Ribavirin produced significant embryocidal and/or teratogenic effects in all animal species in which adequate studies have been conducted. Malformations of the skull, palate, eye, jaw, limbs, skeleton and gastrointestinal tract were noted. The incidence and severity of teratogenic effects increased with escalation of the drug dose. Survival of fetuses and offspring was reduced.

Nursing Mothers: It is not known whether Ribavirin is excreted in human milk. Because many drugs are excreted in human milk and to avoid any potential for serious adverse reactions in nursing infants from ribavirin, a decision should be made either to discontinue nursing or therapy with Ribavirin, based on the importance of the therapy to the mother.

Precautions & Warnings

Birth defects and fetal death with ribavirin: Do not use in pregnancy and for 6 months after treatment. Patients must have a negative pregnancy test prior to therapy, use at least 2 forms of contraception and undergo monthly pregnancy tests. For a male patient, it is very important for his female partner to avoid becoming pregnant during treatment and during the 7 months after treatment and do not have sex with a pregnant women.

Storage Conditions

Keep out of the reach of children. Keep in a cool & dry place. Protect from light.

Alternative brands of Ribavirin

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.